“The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.”
Background
As most of you know, Burzynski’s Holy Grail has been the fact that his invention is the first and only medication to ever cure a diffuse intrinsic brainstem glioma in children. On top of that, Antineoplastons are also the first and only medication to show enough safety and efficacy to ever reach FDA-approval for a Phase 3 trial for this condition. If Antineoplastons (ANP) were approved for this condition, it could create a massive shift in traditional cancer therapy worldwide—as people would begin to request these medications “off-label” by default, even if insurance doesn’t cover it.
Nearly every single scientific discovery has been resisted at the start, only to later be accepted as truth. This is just the world we live in, and the process we must tolerate.